G7 Italy-digi

ADVOCACY
JANSSEN
Healthcare for the people
& societies of tomorrow
Innovation helps
to make possible
the development
of ever-more
effective
treatments
Over the next 24 hours, 353,000 babies
will be born into a world that’s changing
faster than ever, and they will be joining
a generation of two billion people
expected to be born from 2011 to 2025.
Intergovernmental meetings such as the G7 and
G20 provide the platform to ensure that our next
generation, and their children, have greater access
to care, grow up to embrace health and wellness
and possibly survive diseases we consider impossible
to cure today.
Chronic illnesses
The healthcare issues on the table are manifold:
the cost of healthcare will rise as older people make
up larger proportions of countries’ populations
and the prevalence of chronic illnesses increases.
In addition to age related health problems, global
challenges and viral epidemics are on the rise.
Though costs for the treatment of cardiovascular
diseases, cancer and respiratory diseases are
expected to plummet, it is anticipated that over 50%
of global healthcare expenditure will
be spent treating these three leading
causes of death. Moreover, inadequate
public health services can cause broader
social and economic problems such as
low workforce productivity. Meeting
these challenges in times such as ours
with its ecological, political, social
and economic changes and increased
uncertainty requires more than just
scientific and technological innovation.
It takes increased collaboration between
governments, health authorities,
academia and industry with patient care
at the centre. It also requires innovative
financing models rewarding effectiveness and quality
in care, as well as efficiency in budget management;
and sustainable research and development models,
applying technical innovation and medical advance
in cost-effective ways.
Innovation
As a healthcare company Janssen, the
pharmaceutical division of Johnson & Johnson,
is committed to play its part and innovation is
the lifeblood of our work. Our founder, Dr Paul
Janssen, was always very candid and open about the
principles upon which he based his pharmaceutical
research activities. He stimulated an environment
that encouraged curiosity, entrepreneurship and
freedom to operate for his scientists to research
what they saw fit. His non-academic approach
yielded swift success and resulted in the discovery
and production of more than eighty transformative
breakthrough medicines, four of which are listed in
the WHO’s List of Essential Medicines.
Innovation helps to make possible the
development of ever-more effective treatments, less
invasive procedures with shorter recovery times, and
improved patient outcomes. Advances in technology
can help speed diagnoses, ensure medicine
adherence for improved treatment outcomes, and
allow for personalised real-time tracking to support
prevention and facilitate positive lifestyle choices
for improved health through prevention rather
than cure. The development of disease interception
techniques is an area of much promise for us and
one which could help us all build more resilient
healthcare systems If we are able to delay the
development of complications and prevent chronic
illnesses, decreasing overall health expenditures.
Collaboration
More than ever it is clear that we cannot work in
isolation if we are to find solutions to the challenges
before us. Innovation in healthcare is more than
developing medicines that will transform the lives
of patients. It’s about providing a better quality
of service where the patient is at the heart of all
decisions and improving access by keeping costs low.
We believe that a good idea can come from
anywhere and anyone – and we seek to positively
impact human health through innovation and
collaboration worldwide. One of the forms this
collaboration has taken is our network of Innovation
Centers around the world, bringing together a
network of academics, scientists, entrepreneurs and
business development specialists to source the best